Vaccine Boosters in Bahrain Cast Cloud Over Sinopharm Covid Shot
(Bloomberg) --
Concerns are growing over the effectiveness of Sinopharm Group Co.'s vaccines, with Bahrain becoming the first nation to say it would start giving an additional immunization to citizens who are already fully vaccinated with the Chinese shot, Dow Jones reported.
Undersecretary of health Waleed Khalifa Al Manea urged high-risk people -- including those who are over 50, obese or chronically ill -- to get a dose of the mRNA vaccine made by Pfizer Inc. and BioNTech SE six months after completing the Sinopharm vaccine series, according to the report.
While Al Manea said Sinopharm's shot was providing a high degree of protection and noted that it's mostly unvaccinated people that are being hospitalized, the Dow Jones report didn't elaborate as to why he was recommending the added dose of the Pfizer-BioNTech jab. Shots from state-owned Sinopharm account for more than 60% of all vaccinations given to date in the tiny Persian Gulf nation, according to the report.
Bahrain's move could prove a setback for China's vaccine diplomacy, with the world's most populous country pledging to help developing nations get access to immunizations that will help put an end to the Covid-19 pandemic. While Chinese vaccines are being used in dozens of countries, they've been dogged by concerns over their effectiveness and whether they stop transmission, not just serious illness and death.
Mix and Match
Bahrain has seen a steadily rising number of coronavirus cases since the end of 2020, hitting a record of more than 3,000 new infections a day at the end of May. That's despite the fact that it has one of the world's highest immunization rates, with more than 50% of the population fully vaccinated, according to Bloomberg's Covid Vaccine Tracker.
The country's new guidance may feed existing doubt about the Sinopharm shot's potency. It comes after Seychelles, an island off Africa in the Indian Ocean, experienced an outbreak in May despite the fact that it has fully vaccinated more of its population than any other nation in the world. Its primary shot has been from Sinopharm.
Scientists are starting to investigate whether mixing and matching vaccines, particularly those that use different methods to trigger an immune response, will lead to greater protection against Covid-19. The U.S. National Institutes of Health has started an early stage study to examine the effects of giving a booster shot of different vaccines to fully immunized adult volunteers.
Sinopharm officials declined a request for comment from Bloomberg.
The company's vaccine, made from inactivated virus that's injected to trigger an immune response, successfully prevents symptomatic infections and protects people against serious disease, with the two shot series shown as 73%-to-78% effective in a study published last month in the prestigious Journal of the American Medical Association.
Read more: China's Sinopharm Publishes Awaited Covid Vaccine Study Details
The vaccine, plus another from China's Sinovac Biotech Ltd., have formed the backbone of immunization across the developing world, from Hungary to Peru. While their manufacturers have drawn criticism for not sharing more information about their risks and benefits, the World Health Organization recently authorized both for more widespread use across the globe.
©2021 Bloomberg L.P.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.